Company Overview
About Uncommon Bio
Uncommon Bio (formerly Higher Steaks) is a UK-based biotechnology company that underwent a significant strategic pivot in 2024–2025, transitioning from cultivated meat production toward developing scalable biomanufacturing technologies for human therapeutic applications. Founded by Benjamina Bollag, the company was originally focused on developing cultivated pork products using cell culture and bioprocess engineering techniques. In 2025, Uncommon Bio's cultivated meat platform and associated intellectual property were acquired by Meatable, a Netherlands-based cultivated meat company — allowing Uncommon Bio to exit the food application space and redirect its biomanufacturing expertise toward the healthcare and therapeutics sector.
Business Model & Competitive Advantage
Uncommon Bio''s current focus is on applying its cellular agriculture and bioprocess engineering capabilities to therapeutic biomanufacturing challenges — leveraging the company''s expertise in cell line development, bioreactor scale-up, and manufacturing process design for applications in human health. The therapeutics biomanufacturing sector faces significant production bottlenecks for cell-based therapies, gene therapies, and biologics that share fundamental process engineering challenges with cultivated meat production: efficiently growing mammalian cells at scale in bioreactors under controlled conditions. This technology transfer from food to medicine represents a broader trend as cultivated meat companies pivot their bioengineering capabilities toward higher-margin therapeutic markets.
Competitive Landscape 2025–2026
As an early-stage company in active strategic transition, Uncommon Bio''s commercial profile and specific therapeutic program focus are evolving. The company represents an interesting case study in the transferability of cellular agriculture engineering capabilities to healthcare manufacturing — and positions itself at the intersection of precision fermentation, cell biology tooling, and therapeutic contract development and manufacturing (CDMO) markets as it develops its new strategic direction.
Key Differentiators
Emerging Innovator
Uncommon Bio is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Uncommon Bio with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Uncommon Bio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Uncommon Bio Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Uncommon Bio vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →